Research and Markets: This New Strategic Analysis Report “Novo Nordisk: Performance, Products, Pipeline And Potential” Provides a Complete and Critical Review of the Company

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c64451) has announced the addition of Espicom Business Intelligence's new report Novo Nordisk: Performance, Products, Pipeline and Potential to their offering

Novo Nordisk is a biotech-based healthcare company with a broad diabetes product portfolio. It also has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products.

This new strategic analysis report Novo Nordisk: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis.

Pharmaceutical company intelligence reports from us provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Report Content

EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position,
company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS
Key product analysis and forecasting

Diabetes Care
- Levemir (insulin detemir)
- NovoRapid/NovoLog (insulin aspart)
- NovoMix/NovoLog Mix (insulin aspart)
- NovoNorm/Prandin (repaglinide)

Biopharmaceuticals
- NovoSeven (recombinant Factor VIIa)
- Norditropin (somatropin)
- Activelle/Activella (17-beta oestradiol+norethisterone acetate)
- Vagifem (17-beta oestradiol)
- GlucaGen (glucagon)

OPERATIONAL DATA
A wealth of background and detail
- A full 5-year financial performance assessment
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures

Novo Nordisk is a biotech-based healthcare company with the broadest diabetes product portfolio in the industry and a world leader in diabetes care. In addition, it has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy and is currently expanding into the new therapeutic areas of cancer and inflammation. Its products are marketed in 179 countries.

As a focused healthcare company and world leader in diabetes care, Novo Nordisk is committed to maintaining its strong position in this field, which builds on more than 80 years experience. Its diabetes strategy is based on the industry's broadest portfolio of insulin analogues and injection devices, together with cutting-edge research and a wide range of partnerships.

The biopharmaceuticals business is an increasing growth driver for the company, currently fuelled by NovoSeven. Novo Nordisk intends to build a broader biopharmaceuticals business, with new business areas focusing on immunotherapy in cancer and inflammation. The company already has a number of projects in early-phase development in these areas, but they are unlikely to significantly contribute to its business within the next ten years. However, to accelerate this process Novo Nordisk is establishing the technology platform and strengthening the skills base required both in-house and with partners.

Novo Nordisk is working to create a culture of innovation throughout its entire organisation. It recently conducted a review of its capacity to innovate and as a result, a number of projects have been selected for future development. It has previously developed a new technology for prolonging the duration of insulin, which has been used in the development of the insulin analogue, Levemir, and liraglutide. The technology has the potential to be applicable to any biopharmaceutical compound.

Novo Nordisk plans to expand its sales and marketing activities, particularly in the US and Chinese markets.

Companies Mentioned:

- Aradigm Corporation
- Argos Therapeutics
- BioStratum Incorporated
- BioVisioN AG
- Cephalon
- Crucell NV
- GlaxoSmithKline
- G2 Inflammation Pty Ltd
- Innate Pharma SAS
- Medarex Inc
- Morphotek Inc
- Nastech Pharmaceutical
- Neose Technologies Inc
- Sangamo BioSciences Inc
- Sapphire Therapeutics Inc
- Scios Inc
- SR Pharma plc
- Takeda
- Transition Therapeutics Inc
- TransTech Pharma Inc
- ZymoGenetics Inc

For more information visit http://www.researchandmarkets.com/reports/c64451